近年来,血管扩张药在治疗动脉高血压方面已显得越来越重要,这是因为高血压的病理生理因素突出表现在外周动脉阻力增大。因此,能减少外周动脉阻力的药物就能利用血液动力学的有效途径来降低升高的血压。血管扩张药能降低心脏前负荷,现已证明,此类药物尚能在心力衰竭的治疗中用作强心甙和利尿剂的辅助药物。在高血压的血管舒张疗法中,最常用的药物是肼肽嗪和派唑嗪,但由于这些药物存在副作用和药效时间短,影响了其应用。因此,需要开发一种既能舒张血管,又能满足下 In recent years, vasodilators in the treatment of arterial hypertension has become more and more important, because the pathophysiological factors of hypertension prominent in the peripheral arterial resistance increased. Therefore, drugs that reduce peripheral arterial resistance can take advantage of hemodynamic effective routes to reduce elevated blood pressure. Vasodilators reduce the preload of the heart, and it has been shown that such drugs can be used as adjuncts to cardiac glycosides and diuretics in the treatment of heart failure. In the hypertensive vasodilation therapy, the most commonly used drugs are hydrazin and oxazepam, but because of the side effects of these drugs and pharmacological effects of short duration, affecting its application. Therefore, the need to develop a can not only relax the blood vessels, but also to meet the next